Cardiac biomarkers for risk stratification of arrhythmic death in patients with heart failure and reduced ejection fraction

References

• Kadish A, Dyer A, Daubert JP, et al. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med. 2004;350:2151–2158.
   PubMed Web of Science ®Google Scholar
• Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352:225–237.
   PubMed Web of Science ®Google Scholar
• Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346:877–883.
   PubMed Web of Science ®Google Scholar
• Maggioni AP, Dahlström U, Filippatos G, et al. EURObservational research programme: regional differences and 1-year follow-up results of the heart failure pilot survey (ESC-HF Pilot). Eur J Heart Fail. 2013;15:808–817.
   PubMed Web of Science ®Google Scholar
• Priori SG, Blomstrom-Lundqvist C, Mazzanti A, et al. ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: the task force for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death of the European Society of Cardiology (ESC). Endorsed by: association for European Paediatric and Congenital Cardiology (AEPC). Eur Heart J. 2015;36:2793–2867.
   PubMed Web of Science ®Google Scholar
• Ponikowski P, Voors AA, Anker SD, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;2016:2129–2200.
   Web of Science ®Google Scholar
• Dagres N, Hindricks G. Risk stratification after myocardial infarction: is left ventricular ejection fraction enough to prevent sudden cardiac death? Eur Heart J. 2013;34:1964–1971.
   PubMedGoogle Scholar
• Pezawas T, Diedrich A, Robertson D, et al. Risk of arrhythmic death in ischemic heart disease: a prospective, controlled, observer-blind risk stratification over 10 years. Eur J Clin Invest. 2017;47:231–240.
   PubMed Web of Science ®Google Scholar
• Pezawas T, Diedrich A, Winker R, et al. Multiple autonomic and repolarization investigation of sudden cardiac death in dilated cardiomyopathy and controls. Circ Arrhythm Electrophysiol. 2014;7:1101–1108.
   PubMed Web of Science ®Google Scholar
• Yap YG, Duong T, Bland JM, et al. Optimising the dichotomy limit for left ventricular ejection fraction in selecting patients for defibrillator therapy after myocardial infarction. Heart. 2007;93:832–836.
   PubMed Web of Science ®Google Scholar
• Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med. 1998;339:321–328.
   PubMed Web of Science ®Google Scholar
• Bunton DC, Petrie MC, Hillier C, et al. The clinical relevance of adrenomedullin: a promising profile? Pharmacol Ther. 2004;103:179–201.
   PubMed Web of Science ®Google Scholar
• Spieker LE, Noll G, Ruschitzka FT, et al. Endothelin receptor antagonists in congestive heart failure: a new therapeutic principle for the future? J Am Coll Cardiol. 2001;37:1493–1505.
   PubMed Web of Science ®Google Scholar
• Gottlieb SS, Harris K, Todd J, et al. Prognostic significance of active and modified forms of endothelin 1 in patients with heart failure with reduced ejection fraction. Clin Biochem. 2015;48:292–296.
   PubMed Web of Science ®Google Scholar
• Sabatine MS, Morrow DA, de Lemos JA, et al. Evaluation of multiple biomarkers of cardiovascular stress for risk prediction and guiding medical therapy in patients with stable coronary disease. Circulation. 2012;125:233–240.
   PubMed Web of Science ®Google Scholar
• Zhang CL, Xie S, Qiao X, et al. Plasma endothelin-1-related peptides as the prognostic biomarkers for heart failure: a PRISMA-compliant meta-analysis. Medicine (Baltimore). 2017;96:e9342.
   PubMed Web of Science ®Google Scholar
• Funke-Kaiser A, Mann K, Colquhoun D, et al. Midregional proadrenomedullin and its change predicts recurrent major coronary events and heart failure in stable coronary heart disease patients: the LIPID study. Int J Cardiol. 2014;172:411–418.
   PubMed Web of Science ®Google Scholar
• Fraty M, Velho G, Gand E, et al. Prognostic value of plasma MR-proADM vs NT-proBNP for heart failure in people with type 2 diabetes: the SURDIAGENE prospective study. Diabetologia. 2018;61:2643–2653.
   PubMed Web of Science ®Google Scholar
• Lindberg S, Jensen JS, Pedersen SH, et al. MR-proANP improves prediction of mortality and cardiovascular events in patients with STEMI. Eur J Prev Cardiol. 2015;22:693–700.
   PubMed Web of Science ®Google Scholar
• Seronde MF, Gayat E, Logeart D, et al. Comparison of the diagnostic and prognostic values of B-type and atrial-type natriuretic peptides in acute heart failure. Int J Cardiol. 2013;168:3404–3411.
   PubMed Web of Science ®Google Scholar
• Hinkle LE Jr., Thaler HT. Clinical classification of cardiac deaths. Circulation. 1982;65:457–464.
   PubMed Web of Science ®Google Scholar
• Burger AL, Stojkovic S, Diedrich A, et al. Elevated plasma levels of asymmetric dimethylarginine and the risk for arrhythmic death in ischemic and non-ischemic, dilated cardiomyopathy - A prospective, controlled long-term study. Clin Biochem. 2020;2020:37–42.
   Google Scholar
• Pezawas T, Burger AL, Binder T, et al. Importance of diastolic function for the prediction of arrhythmic death: a prospective, observer-blinded, long-term study. Circ Arrhythm Electrophysiol. 2020;13:e007757.
   PubMed Web of Science ®Google Scholar
• Hauser JA, Demyanets S, Rusai K, et al. Diagnostic performance and reference values of novel biomarkers of paediatric heart failure. Heart. 2016;102:1633–1639.
   PubMed Web of Science ®Google Scholar
• Struck J, Tao C, Morgenthaler NG, et al. Identification of an Adrenomedullin precursor fragment in plasma of sepsis patients. Peptides. 2004;25:1369–1372.
   PubMed Web of Science ®Google Scholar
• Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988;332:411–415.
   PubMed Web of Science ®Google Scholar
• Mayyas F, Niebauer M, Zurick A, et al. Association of left atrial endothelin-1 with atrial rhythm, size, and fibrosis in patients with structural heart disease. Circ Arrhythm Electrophysiol. 2010;3:369–379.
   PubMed Web of Science ®Google Scholar
• Peng T, Li X, Hu Z, et al. Predictive role of endothelin in left ventricular remodeling of chronic kidney disease. Ren Fail. 2018;40:183–186.
   PubMed Web of Science ®Google Scholar
• Valero-Munoz M, Li S, Wilson RM, et al. Dual Endothelin-A/Endothelin-B receptor blockade and cardiac remodeling in heart failure with preserved ejection fraction. Circ Heart Fail. 2016;9:11.
   Web of Science ®Google Scholar
• Khan SQ, Dhillon O, Struck J, et al. C-terminal pro-endothelin-1 offers additional prognostic information in patients after acute myocardial infarction: leicester acute myocardial infarction peptide (LAMP) Study. Am Heart J. 2007;154:736–742.
   PubMed Web of Science ®Google Scholar
• Khan SQ, Dhillon O, Kelly D, et al. Plasma N-terminal B-Type natriuretic peptide as an indicator of long-term survival after acute myocardial infarction: comparison with plasma midregional pro-atrial natriuretic peptide: the LAMP (Leicester acute myocardial infarction peptide) study. J Am Coll Cardiol. 2008;51:1857–1864.
   PubMed Web of Science ®Google Scholar
• von Haehling S, Jankowska EA, Morgenthaler NG, et al. Comparison of midregional pro-atrial natriuretic peptide with N-terminal pro-B-type natriuretic peptide in predicting survival in patients with chronic heart failure. J Am Coll Cardiol. 2007;50:1973–1980.
   PubMed Web of Science ®Google Scholar
• Jougasaki M, Burnett JC Jr. Adrenomedullin: potential in physiology and pathophysiology. Life Sci. 2000;66:855–872.
   PubMed Web of Science ®Google Scholar
• Samson WK. Adrenomedullin and the control of fluid and electrolyte homeostasis. Ann Rev Physiol. 1999;61:363–389.
   PubMed Web of Science ®Google Scholar
• Ihara T, Ikeda U, Tate Y, et al. Positive inotropic effects of adrenomedullin on rat papillary muscle. Eur J Pharmacol. 2000;390:167–172.
   PubMed Web of Science ®Google Scholar
• Von Haehling S, Filippatos GS, Papassotiriou J, et al. Mid-regional pro-adrenomedullin as a novel predictor of mortality in patients with chronic heart failure. Eur J Heart Fail. 2010;12:484–491.
   PubMed Web of Science ®Google Scholar
• Tsuruda T, Burnett JC Jr. Adrenomedullin: an autocrine/paracrine factor for cardiorenal protection. Circ Res. 2002;90:625–627.
   PubMed Web of Science ®Google Scholar
• Welsh P, Kou L, Yu C, et al. Prognostic importance of emerging cardiac, inflammatory, and renal biomarkers in chronic heart failure patients with reduced ejection fraction and anaemia: RED-HF study. Eur J Heart Fail. 2018;20:268–277.
   PubMed Web of Science ®Google Scholar
• Moertl D, Berger R, Struck J, et al. Comparison of midregional pro-atrial and B-type natriuretic peptides in chronic heart failure: influencing factors, detection of left ventricular systolic dysfunction, and prediction of death. J Am Coll Cardiol. 2009;53:1783–1790.
   PubMed Web of Science ®Google Scholar